[go: up one dir, main page]

MX2009012613A - Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. - Google Patents

Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.

Info

Publication number
MX2009012613A
MX2009012613A MX2009012613A MX2009012613A MX2009012613A MX 2009012613 A MX2009012613 A MX 2009012613A MX 2009012613 A MX2009012613 A MX 2009012613A MX 2009012613 A MX2009012613 A MX 2009012613A MX 2009012613 A MX2009012613 A MX 2009012613A
Authority
MX
Mexico
Prior art keywords
heteroaryl substituted
compounds
antiviral agents
substituted thiazoles
methods
Prior art date
Application number
MX2009012613A
Other languages
English (en)
Inventor
Dawei Chen
Milind Deshpande
Avinash Phadke
Xiangzhu Wang
Jesse Quinn
Shouming Li
Suoming Zhang
Cuixian Liu
Venkat Gadhachanda
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of MX2009012613A publication Critical patent/MX2009012613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invenci?n proporciona compuestos de tiazolo substituidos por heteroarilo de la F?rmula I y II y las sales farmac?uticamente aceptables de los mismos. Las variables A y de R3 a R7 son como aqu? se definen. La presente invenci?n tambi?n incluye m?todos de preparaci?n de compuestos y sales de la F?rmula I y II. La presente invenci?n tambi?n incluye composiciones farmac?uticas que contienen el tiazolo substituido por heteroarilo, compuestos y m?todos para utilizar los compuestos de tiazolo substituido por heteroarilo, incluyendo los m?todos de uso de los compuestos en el tratamiento del virus de la hepatitis C.
MX2009012613A 2007-05-22 2008-05-22 Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. MX2009012613A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93942407P 2007-05-22 2007-05-22
PCT/US2008/006676 WO2008147557A2 (en) 2007-05-22 2008-05-22 Heteroaryl substituted thiazoles and their use as antiviral agents

Publications (1)

Publication Number Publication Date
MX2009012613A true MX2009012613A (es) 2010-04-21

Family

ID=39739656

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012613A MX2009012613A (es) 2007-05-22 2008-05-22 Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.

Country Status (12)

Country Link
US (1) US8183263B2 (es)
EP (1) EP2164846A2 (es)
JP (1) JP2010528019A (es)
KR (1) KR20100020484A (es)
CN (1) CN101801964A (es)
AU (1) AU2008257158A1 (es)
BR (1) BRPI0811939A2 (es)
CA (1) CA2687817A1 (es)
EA (1) EA200901573A1 (es)
IL (1) IL202139A0 (es)
MX (1) MX2009012613A (es)
WO (1) WO2008147557A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101247807A (zh) * 2005-05-09 2008-08-20 艾其林医药公司 噻唑化合物及使用方法
NZ570835A (en) * 2006-03-08 2011-11-25 Achillion Pharmaceuticals Inc Substituted aminothiazole derivatives with anti-HCV activity
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
US8106209B2 (en) * 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2009155389A1 (en) * 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Triazolopyridine compounds useful as kinase inhibitors
KR101931311B1 (ko) 2011-05-27 2018-12-20 아칠리온 파르마세우티칼스 인코포레이티드 Ｈｃｖ 감염 치료에 유용한 치환된 앨리팬, 시클로팬, 헤테라팬, 헤테로팬, 헤테로-헤테라팬 및 메탈로센
US9278089B2 (en) 2011-10-26 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating HCV infection with a small molecule CHK2 inhibitor
TWI475016B (zh) * 2012-05-11 2015-03-01 北京貝美拓新藥研發有限公司 一組提高激酶活性的化合物及其應用
WO2014135423A1 (en) * 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag N-heteroaryl substituted aniline derivatives as hcv-antivirals
US10532987B2 (en) * 2015-02-17 2020-01-14 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Science Compounds and methods for inducing browning of white adipose tissue
EP3262040A4 (en) * 2015-02-27 2018-09-12 The Regents of The University of California Small molecules that enable cartilage rejuvanation
CN106467501B (zh) * 2015-08-18 2018-10-26 中国医学科学院医药生物技术研究所 新型抗病毒化合物
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
HRP20251564T1 (hr) 2022-05-19 2026-01-30 Astrazeneca Ab Amidni heteroaromatski spojevi korisni u liječenju bolesti jetre

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467666A (en) 1966-11-07 1969-09-16 Geigy Chem Corp 2-substituted aminothiazoles
BE795907A (fr) 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
CA2206315A1 (en) 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
WO2000006575A2 (en) 1998-07-28 2000-02-10 Smithkline Beecham Plc Azabicyclic compounds
WO2000017175A1 (en) 1998-09-18 2000-03-30 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
EP1135126A4 (en) 1998-12-07 2003-04-02 Smithkline Beecham Corp MYT1 KINASE INHIBITORS
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001064674A1 (en) 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
US6586453B2 (en) 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
JP4145654B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する環状化合物
IL160329A0 (en) 2001-08-13 2004-07-25 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives
CA2461363A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
EP1482940A2 (en) 2001-10-03 2004-12-08 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
EP1452530A4 (en) 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
US6936629B2 (en) 2001-12-21 2005-08-30 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
EP1473082B1 (en) 2002-02-06 2013-10-09 JX Nippon Oil & Energy Corporation Method for preparing a hydroraffination catalyst
US20050239852A1 (en) 2002-08-02 2005-10-27 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
AU2004212494B2 (en) 2003-02-10 2011-03-17 Vertex Pharmaceuticals Incorporated Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
US20040192743A1 (en) 2003-02-12 2004-09-30 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
ATE393243T1 (de) 2003-02-27 2008-05-15 Ab Science Diagnostisches verfahren der mastozytose
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
CA2521915A1 (en) 2003-04-15 2004-10-28 Pfizer Inc. Alpha substituted carboxylic acid as ppar modulators
JP2006525312A (ja) 2003-04-28 2006-11-09 アブ サイエンス 脳虚血を治療するためのチロシンキナーゼ阻害剤の使用方法
WO2004098612A2 (en) 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005016323A2 (en) 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
US20070269420A1 (en) 2003-11-24 2007-11-22 Chunduru Srinivas K Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases
CN100509808C (zh) 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 新型噻唑衍生物
WO2005073225A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005099673A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycylic thiazoles as potassium ion channel modulators
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
US20080146585A1 (en) 2004-04-20 2008-06-19 Ab Science Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy
CA2564570A1 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating plasmodium related diseases
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
EP1742633A2 (en) 2004-04-23 2007-01-17 AB Science Use of c-kit inhibitors for treating fibrosis
CA2566104A1 (en) 2004-05-18 2005-12-01 Ab Science Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
WO2006028029A1 (ja) 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
MX2007003377A (es) 2004-09-23 2007-05-10 Pfizer Prod Inc Agonistas del receptor de trombopoyetina.
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
CN101247807A (zh) * 2005-05-09 2008-08-20 艾其林医药公司 噻唑化合物及使用方法
AU2006243987B2 (en) 2005-05-11 2011-11-24 Abbott Laboratories Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
EP1904065A2 (en) 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
US20070135368A1 (en) 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
AU2007209903B2 (en) 2006-02-01 2012-09-13 Merck Sharp & Dohme Corp. Potassium channel inhibitors
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
NZ570835A (en) 2006-03-08 2011-11-25 Achillion Pharmaceuticals Inc Substituted aminothiazole derivatives with anti-HCV activity
WO2008033932A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors

Also Published As

Publication number Publication date
WO2008147557A2 (en) 2008-12-04
CN101801964A (zh) 2010-08-11
US20090041720A1 (en) 2009-02-12
BRPI0811939A2 (pt) 2014-11-25
WO2008147557A3 (en) 2009-03-05
KR20100020484A (ko) 2010-02-22
AU2008257158A1 (en) 2008-12-04
EA200901573A1 (ru) 2010-04-30
US8183263B2 (en) 2012-05-22
EP2164846A2 (en) 2010-03-24
IL202139A0 (en) 2010-06-16
CA2687817A1 (en) 2008-12-04
JP2010528019A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
NZ595186A (en) Di-pyrazolidinyl-biphenylyl compounds for treating hepatitis C virus (HCV) infection
MY155517A (en) Heterocyclic derivatives
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
GB0612423D0 (en) Therapeutic agents
NZ703064A (en) Inhibitors of hepatitis c virus
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
UA110259C2 (uk) Похідні піролопіримідину і пурину
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
WO2012125926A3 (en) Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
IN2012DN01855A (es)
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
GB0413087D0 (en) Therapeutic compounds
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal